Compare Summit Therapeutics Inc (SMMT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Yum China Holdings Inc trades at $47.71 (market cap $16.28B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | YUMC | |
|---|---|---|
Market Cap | $12.06B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.98 | $57.95 |
52-Week Low | $12.55 | $40.18 |
Enterprise Value | $11.39B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
YUMC trades at $47.92, down 0.56% on the day, with a bullish technical signal supported by moving averages. The company demonstrates consistent fundamental strength with Q2 2026 earnings beating estimates, revenue growth of 13% year-over-year, and a net income margin of 7.84%. Recent completion of the Pizza Hut China acquisition for $1.2 billion positions the company for strategic growth and cost synergies.
The outlook remains positive with strong analyst support (73.68% buy ratings) and a 26.21% upside potential. Key risks include Chinese macroeconomic headwinds and integration challenges from the Pizza Hut acquisition. Earnings momentum and valuation metrics suggest continued growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
